382 related articles for article (PubMed ID: 32530932)
101. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
[TBL] [Abstract][Full Text] [Related]
102. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
Izawa N; Masuishi T; Takahashi N; Shoji H; Yamamoto Y; Matsumoto T; Sugiyama K; Kajiwara T; Kawakami K; Aomatsu N; Kondoh C; Kawakami H; Takegawa N; Esaki T; Shimokawa M; Nishio K; Narita Y; Hara H; Sunakawa Y; Boku N; Moriwaki T; Eguchi Nakajima T; Muro K
Target Oncol; 2023 May; 18(3):369-381. PubMed ID: 37148491
[TBL] [Abstract][Full Text] [Related]
103. Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice.
Giuliani J; Insolda J; Pigozzi E; Bonetti A
Recenti Prog Med; 2020 Dec; 111(12):785-787. PubMed ID: 33362177
[No Abstract] [Full Text] [Related]
104. Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Ding PQ; Dolley A; Cheung WY
Curr Oncol; 2022 Dec; 30(1):130-144. PubMed ID: 36661660
[TBL] [Abstract][Full Text] [Related]
105. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
Shitara K; George B; Taieb J; Sundar R; Fakih MG; Makris L; Benhadji KA; Ghidini M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9361-9374. PubMed ID: 37213030
[TBL] [Abstract][Full Text] [Related]
106. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
[TBL] [Abstract][Full Text] [Related]
107. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Kuboki Y; Watanabe J; Terazawa T; Kawakami H; Yokota M; Nakamura M; Kotaka M; Sugimoto N; Ojima H; Oki E; Kajiwara T; Yamamoto Y; Tsuji Y; Denda T; Tamura T; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Target Oncol; 2024 Jan; 19(1):59-69. PubMed ID: 38194163
[TBL] [Abstract][Full Text] [Related]
108. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
Xu J; Kim TW; Shen L; Sriuranpong V; Pan H; Xu R; Guo W; Han SW; Liu T; Park YS; Shi C; Bai Y; Bi F; Ahn JB; Qin S; Li Q; Wu C; Ma D; Lin D; Li J
J Clin Oncol; 2018 Feb; 36(4):350-358. PubMed ID: 29215955
[TBL] [Abstract][Full Text] [Related]
109. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
[TBL] [Abstract][Full Text] [Related]
110. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
[TBL] [Abstract][Full Text] [Related]
111. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
[TBL] [Abstract][Full Text] [Related]
112. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
[TBL] [Abstract][Full Text] [Related]
113. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.
Varghese AM; Cardin DB; Hersch J; Benson AB; Hochster HS; Makris L; Hamada K; Berlin JD; Saltz LB
Clin Cancer Res; 2020 Apr; 26(7):1555-1562. PubMed ID: 31924737
[TBL] [Abstract][Full Text] [Related]
114. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Saif MW; Becerra CR; Fakih MG; Sun W; Popovic L; Krishnamurthi S; George TJ; Rudek MA; Shepard DR; Skopek J; Sramek V; Zaric B; Yamamiya I; Benhadji KA; Hamada K; He Y; Rosen L
Cancer Chemother Pharmacol; 2021 Sep; 88(3):485-497. PubMed ID: 34097100
[TBL] [Abstract][Full Text] [Related]
115. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
[TBL] [Abstract][Full Text] [Related]
116. Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
Fujimoto Y; Nakanishi R; Nukatsuka M; Matsuoka K; Ando K; Wakasa T; Kitao H; Oki E; Maehara Y; Mori M
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1029-1038. PubMed ID: 32322913
[TBL] [Abstract][Full Text] [Related]
117. Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer.
Nukatsuka M; Fujioka A; Nagase H; Tanaka G; Hayashi H
Chemotherapy; 2023; 68(2):102-110. PubMed ID: 36623495
[TBL] [Abstract][Full Text] [Related]
118. Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Yoshino T; Van Cutsem E; Li J; Shen L; Kim TW; Sriuranpong V; Xuereb L; Aubel P; Fougeray R; Cattan V; Amellal N; Ohtsu A; Mayer RJ
ESMO Open; 2022 Jun; 7(3):100511. PubMed ID: 35688062
[TBL] [Abstract][Full Text] [Related]
119. Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.
Doleschal B; Taghizadeh H; Lentner T; Riedl JM; Granitzer J; Morariu D; Decker J; Aichberger KJ; Webersinke G; Kirchweger P; Petzer A; Rumpold H
ESMO Open; 2023 Dec; 8(6):102064. PubMed ID: 37977001
[TBL] [Abstract][Full Text] [Related]
120. Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Oshima K; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Boku N
PLoS One; 2022; 17(6):e0269115. PubMed ID: 35653412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]